







CD Markers

Antibodies Targeting CD





bioxcell.com



CD Marker Antibodies




Antigen	Reactivity	Application	Clone	Catalog Number	Isotype Control
CD103	Mouse	<i>in vivo</i> CD103 neutralization, IF, FC	M290	BE0026	BE0089
CD106	Mouse	<i>in vivo</i> VCAM-1 neutralization, IF	M/K-2.7	BE0027	BE0088
CD115 (CSF1R)	Mouse	<i>in vivo</i> macrophage depletion, <i>in vitro</i> CSF1R neutralization, <i>in vivo</i> monocyte depletion, FC, WB	AFS98	BE0213	BE0089
CD115 (CSF1R)	Human	<i>in vitro</i> CSF1R neutralization, IHC-P, Functional assays, FC	2-4A5-4	BE0347	BE0088
CD115 (CSF1R)	Mouse	<i>in vivo</i> macrophage depletion, <i>in vitro</i> CSF1R neutralization, <i>in vivo</i> monocyte depletion, FC, WB	AFS98	BP0213	BP0089
CD117 (c-Kit)	Mouse	FC, IF Immunohistochemistry	2B8	BE0280	BE0090
CD117 (c-Kit)	Mouse	<i>in vivo</i> mast cell depletion, <i>in vivo</i> c-Kit+ cell depletion, <i>in vitro</i> c-Kit neutralization, IP, FC	ACK2	BE0293	BE0090
CD117 (c-Kit)	Human	<i>in vivo</i> c-Kit+ cell depletion, <i>in vitro</i> c-Kit targeting, IHC-F	SR-1	BE0380	BE0085
CD119 (IFN γ R)	Mouse	<i>in vivo</i> IFN γ R neutralization, <i>in vitro</i> IFN γ R neutralization	GR-20	BE0029	BE0089
CD119 (IFN γ R α)	Mouse	WB, IP, Flow cytometry	2E2	BE0287	BE0091
CD11a	Human	Functional assays, FC	R7-1	BE0192	BE0083
CD11a (LFA-1 α)	Human	<i>in vitro</i> LFA-1 neutralization	TS-1/22.1.1.13	BE0005	BE0083
CD11a (LFA-1 α)	Mouse	<i>in vivo</i> LFA-1 neutralization	FD441.8	BE0005-1	BE0090
CD11a (LFA-1 α)	Mouse	<i>in vivo</i> LFA-1 neutralization, FC	M17/4	BE0006	BE0089
CD11b	Human, Mouse	<i>in vivo</i> CD11b neutralization, ILC2 cell purification, FC	M1/70	BE0007	BE0090
CD11b	Mouse	<i>in vivo</i> CD11b neutralization, <i>in vitro</i> CD11b neutralization, FC, IF, Immunohistochemistry, IP	5C6	BE0428	BE0090
CD120b (TNFR2)	Mouse	<i>in vivo</i> TNFR2 blockade, <i>in vitro</i> TNFR2 blockade	TR75-54.7	BE0247	BE0091
CD121a (IL-1 R)	Mouse	<i>in vivo</i> IL-1 R blockade, <i>in vitro</i> IL-1 R blockade	JAMA-147	BE0256	BE0091
CD122	Mouse	<i>in vitro</i> NK cell negative selection, IP, FC	5H4	BE0272	BE0089
CD122	Mouse	<i>in vivo</i> NK cell depletion, <i>in vivo</i> CD122 blockade, <i>in vitro</i> IL-2R blockade, Functional assays, FC	TM-Beta 1	BE0298	BE0090
CD127 (IL-7R α)	Mouse	<i>in vivo</i> blocking of IL-7R α signaling, FC	A7R34	BE0065	BE0089
CD132	Mouse	<i>in vivo</i> γ c blockade, Functional assays, IP, FC	3E12	BE0271	BE0090
CD134 (OX40)	Mouse	<i>in vivo</i> OX40 activation, <i>in vitro</i> OX40 activation, WB	OX-86	BE0031	BE0088
CD134 (OX40)	Mouse	<i>in vivo</i> OX40 activation, <i>in vitro</i> OX40 activation, WB	OX-86	BP0031	BP0088
CD134L(OX40L)	Mouse	<i>in vivo</i> blocking of OX40/OX40L signaling, <i>in vitro</i> OX40L neutralization	RM134L	BE0033-1	BE0090
CD137 (4-1BB)	Mouse	<i>in vivo</i> activation of 4-1BB	LOB12.3	BE0169	BE0088
CD137 (4-1BB)	Mouse	<i>in vivo</i> 4-1BB stimulation, <i>in vitro</i> 4-1BB stimulation	3H3	BE0239	BE0089
CD137 (4-1BB)	Mouse	<i>in vitro</i> 4-1BB blockade, FC	17B5	BE0296	BE0087
CD137 (4-1BB)	Mouse	<i>in vivo</i> activation of 4-1BB	LOB12.3	BP0169	BP0088
CD137 (4-1BB)	Mouse	<i>in vivo</i> 4-1BB stimulation, <i>in vitro</i> 4-1BB stimulation	3H3	BP0239	BP0089
CD137L (4-1BBL)	Mouse	<i>in vivo</i> 4-1BBL blockade, ELISA	TKS-1	BE0110	BE0089
CD152 (CTLA-4)	Mouse	<i>in vivo</i> CTLA-4 neutralization, <i>in vitro</i> CTLA-4 neutralization, FC, WB	UC10-4F10-11	BE0032	BE0091
CD152 (CTLA-4)	Mouse	<i>in vivo</i> CTLA-4 neutralization, <i>in vitro</i> CTLA-4 neutralization, WB	9H10	BE0131	BE0087
CD152 (CTLA-4)	Mouse	<i>in vivo</i> CTLA-4 neutralization, WB, <i>in vivo</i> intra-tumoral regulatory T cell depletion	9D9	BE0164	BE0086
CD152 (CTLA-4)	Human	<i>in vitro</i> CTLA-4 neutralization, FC	BN13	BE0190	BE0085
CD152 (CTLA-4)	Rat	<i>in vitro</i> CTLA-4 neutralization, FC	WKH203	BE0424	BE0083
CD152 (CTLA-4)	Mouse	<i>in vivo</i> CTLA-4 neutralization, <i>in vitro</i> CTLA-4 neutralization, FC, WB	UC10-4F10-11	BP0032	BP0091
CD152 (CTLA-4)	Mouse	<i>in vivo</i> CTLA-4 neutralization, <i>in vitro</i> CTLA-4 neutralization, WB	9H10	BP0131	BP0087
CD152 (CTLA-4)	Mouse	<i>in vivo</i> CTLA-4 neutralization, WB, <i>in vivo</i> intra-tumoral regulatory T cell depletion	9D9	BP0164	BP0086
CD16.2	Mouse	<i>in vivo</i> CD16.2 blockade, <i>in vitro</i> CD16.2 blockade, FC	9E9	BE0378	BE0091
CD16/CD32	Mouse	<i>in vivo</i> Fc receptor blocking, Fc receptor blocking, FC, Fc receptor blocking, IF	2.4G2	BE0307	BE0090
CD16/CD32	Mouse	<i>in vivo</i> Fc receptor blocking, Fc receptor blocking, FC, Fc receptor blocking, IF	2.4G2	BP0307	BP0090
CD162 (PSGL-1)	Mouse	<i>in vivo</i> PSGL-1 blockade, IHC-F	4RA10	BE0186	BE0088
CD172a	Mouse	<i>in vivo</i> SIRP α blocking, <i>In vitro</i> SIRP α blocking, WB, IP, FC	P84	BE0322	BE0088
CD178 (FasL)	Mouse	<i>in vivo</i> FasL blockade, <i>In vitro</i> FasL blockade, Functional assay, IHC-P, FC	MFL3	BE0319	BE0091
CD18	Mouse	<i>in vivo</i> LFA-1 neutralization	M18/2	BE0009	BE0089
CD183 (CXCR3)	Mouse	<i>in vivo</i> CXCR3 neutralization, FC	CXCR3-173	BE0249	BE0091
CD19	Mouse	<i>in vivo</i> B cell depletion, <i>in vivo</i> CD19 neutralization, <i>in vitro</i> B cell negative selection, FC	1D3	BE0150	BE0089
CD19	Human	FC, Functional assays, IF Chimeric antigen receptor construction (see Poirot, L., et al. reference)	4G7	BE0281	BE0083




Antigen	Reactivity	Application	Clone	Catalog Number	Isotype Control
CD193 (CCR3)	Mouse	<i>in vivo</i> eosinophil depletion	6S2-19-4	BE0316	BE0090
CD1a	Human	<i>in vitro</i> CD1a blockade, FC	OKT-6	BE0211	BE0083
CD1d	Mouse	<i>in vivo</i> CD1d neutralization, <i>in vitro</i> CD1d neutralization	19G11	BE0000	BE0088
CD1d	Mouse	iNKT cell neutralization, <i>in vivo</i> CD1d blockade, FC	20H2 (HB323)	BE0179	BE0088
CD2	Human	<i>in vivo</i> CD2 blockade in huCD2tg mice	CB.219	BE0354	BE0086
CD2	Human	<i>in vivo</i> T cell depletion, <i>in vivo</i> prevention of graft rejection, <i>in vitro</i> inhibition of MLR, Functional assays, IHC-F, ELISA	LO-CD2a	BE0406	BE0090
CD2	Rat	<i>in vivo</i> CD2 blockade, <i>in vitro</i> CD2 blockade, WB	OX-34	BE0417	BE0085
CD20	Human, Monkey	<i>in vivo</i> B cell depletion in hCD20 Tg mice, IHC-F, IP, FC	2H7	BE0276	BE0086
CD20	Mouse	FC, WB, Not recommended for <i>in vivo</i> B cell depletion	AISB12	BE0302	BE0089
CD20	Mouse	<i>in vivo</i> B cell depletion, WB	MB20-11	BE0356	BE0366
CD20	Mouse	<i>in vivo</i> B cell depletion, WB	MB20-11	BP0356	BP0366
CD200	Mouse	<i>in vivo</i> CD200 blockade, <i>in vitro</i> CD200 blockade, IHC-F, IF, FC	OX-90	BE0299	BE0089
CD205	Mouse	<i>in vivo</i> antigen-targeting to DEC-205, <i>in vitro</i> antigen-targeting to DEC-205, IHC-F, IF, FC	NLDC-145	BE0420	BE0089
CD209b	Mouse	<i>in vivo</i> SIGN-R1 blockade, IHC-F, WB, , FC	22D1	BE0220	BE0091
CD210 (IL-10R)	Mouse	<i>in vivo</i> blocking of IL-10/IL-10R signaling, <i>in vitro</i> blocking of IL-10R signaling, FC, WB	1B1.3A	BE0050	BE0088
CD210 (IL-10R)	Mouse	<i>in vivo</i> blocking of IL-10/IL-10R signaling, <i>in vitro</i> blocking of IL-10R signaling, FC, WB	1B1.3A	BP0050	BP0088
CD22	Mouse	<i>in vivo</i> B cell depletion in combination with anti-CD19 (clone 1D3) and anti-rat κ Light Chain (clone MAR 18.5), FC, IP	Cy34.1	BE0011	BE0083
CD220	Human	WB	IR 83-22	BE0338	BE0083
CD227 (MUC1)	Human	<i>in vivo</i> administration in mouse xenograft models, IHC-P, IF, <i>in vitro</i> cell cytotoxicity assay, WB	C595 (NCR48)	BE0336	BE0093
CD24	Mouse	<i>in vivo</i> administration, IHC-F, IHC-P, IF, FC	M1/69	BE0360	BE0090
CD243 (MDR-1)	Human, Monkey	<i>in vivo</i> MDR-1 blocking/depletion in xenogeneic murine, tumor models, <i>in vitro</i> MDR-1 blocking, IHC-P	UIC2	BE0340	BE0085
CD25	Mouse	<i>in vivo</i> regulatory T cell depletion, FC	PC-61.5.3	BE0012	BE0088
CD25	Human	<i>in vivo</i> regulatory T cell depletion in humanized mice, IP, IF	7G7B6	BE0014	BE0085
CD25	Mouse	<i>in vivo</i> regulatory T cell depletion, FC	PC-61.5.3	BP0012	BP0088
CD254 (RANKL)	Mouse	<i>in vivo</i> RANKL blockade	IK22/5	BE0191	BE0089
CD262 (DR5)	Mouse	<i>in vivo</i> induction TRAIL-mediated apoptosis, <i>in vitro</i> induction TRAIL-mediated apoptosis	MD5-1	BE0161	BE0091
CD27	Mouse	<i>in vivo</i> CD27 stimulation, <i>in vitro</i> CD27 stimulation, IP, FC	RM27-3E5	BE0348	BE0089
CD272 (BTLA)	Mouse	<i>in vivo</i> BTLA stimulation, <i>in vivo</i> BTLA blockade	6A6	BE0132	BE0091
CD272 (BTLA)	Mouse	<i>in vivo</i> stimulation of BTLA, <i>in vitro</i> stimulation of BTLA, FC	PK18.6	BE0153	BE0088
CD272 (BTLA)	Mouse	<i>in vivo</i> BTLA blockade, <i>in vitro</i> T cell stimulation/activation, FC	PJ196	BE0196	BE0083
CD272 (BTLA)	Mouse	FC	8F4	BE0210	BE0083
CD272 (BTLA)	Mouse	<i>in vivo</i> BTLA+ B cell and CD4 T cell depletion*, FC, *see description for details	6F7	BE0304	BE0083
CD272 (BTLA)	Mouse	<i>in vivo</i> BTLA blockade, FC	HMBT-6B2	BE0364	BE0091
CD275 (ICOSL)	Mouse	<i>in vivo</i> ICOSL neutralization	HK5.3	BE0028	BE0089
CD276	Mouse	<i>in vivo</i> B7-H3 blockade, FC	MJ18	BE0124	BE0088
CD278 (ICOS)	Human, Monkey, Mouse, Rat	<i>in vitro</i> T cell stimulation/activation, FC, IP	C398.4A	BE0353	BE0091
CD279 (PD-1)	Mouse	<i>in vivo</i> blocking of PD-1/PD-L signaling, <i>in vitro</i> PD-1 neutralization, WB	J43	BE0033-2	BE0091
CD279 (PD-1)	Mouse	<i>in vivo</i> blocking of PD-1/PD-L signaling	RMP1-14	BE0146	BE0089
CD279 (PD-1)	Human	<i>in vitro</i> PD-1 neutralization, <i>in vivo</i> PD-1 blockade in humanized mice	J116	BE0188	BE0083
CD279 (PD-1)	Human	<i>in vivo</i> PD-1 blockade in humanized mice, FC	J110	BE0193	BE0083
CD279 (PD-1)	Mouse	<i>in vivo</i> blocking of PD-1/PD-L signaling, <i>in vitro</i> PD-1 neutralization, IHC-F, IF, WB, FC	29F.1A12™	BE0273	BE0089
CD279 (PD-1)	Mouse	<i>in vivo</i> blocking of PD-1/PD-L signaling, <i>in vitro</i> PD-1 neutralization, WB	J43	BP0033-2	BP0091
CD279 (PD-1)	Mouse	<i>in vivo</i> blocking of PD-1/PD-L signaling	RMP1-14	BP0146	BP0089
CD279 (PD-1)	Mouse	<i>in vivo</i> blocking of PD-1/PD-L signaling, <i>in vitro</i> PD-1 neutralization, IHC-F, IF, WB, FC	29F.1A12™	BP0273	BP0089
CD279 (phosphorylated PD-1)	Human, Mouse	WB, FC	407.6G12	BE0387	BE0085
CD28	Mouse	<i>in vitro</i> T cell stimulation/activation, <i>in vivo</i> CD28 blockade	37.51	BE0015-1	BE0087

α-mouse CD309 (VEGFR-2) (BP0060)



α-mouse CD134 (OX40) (BP0031)



InVivoMab vs. InVivoPlus

	InVivoMab > 95%	InVivoPlus > 95%
purity level		
protein aggregates validated at ≤ 5%		✓
azide and carrier protein free	✓	✓
endotoxin concentration	< 2EU/mg	< 1EU/mg
validated by immunoblot, FC, or ELISA		✓
tested for murine pathogens		✓
available in bulk quantities	✓	✓

Antigen	Reactivity	Application	Clone	Catalog Number	Isotype Control
CD28	Mouse	<i>in vitro</i> T cell stimulation/activation	PV-1	BE0015-5	BE0091
CD28	Rat	<i>in vitro</i> T cell stimulation/activation, FC	JJ319	BE0040	BE0083
CD28	Human	<i>in vitro</i> T cell stimulation/activation	9.3	BE0248	BE0085
CD28	Human, Monkey	<i>in vitro</i> T cell stimulation/activation, IP, FC, IHC-F	CD28.2	BE0291	BE0083
CD28	Mouse	<i>in vivo</i> T cell stimulation/activation, <i>in vitro</i> T cell stimulation/activation	D665	BE0328	BE0083
CD28	Rat	<i>in vivo</i> T cell stimulation/activation	JJ316	BE0418	BE0083
CD29	Mouse	<i>in vivo</i> CD29 neutralization, <i>in vitro</i> CD29 neutralization, IF, FC	KMI6	BE0232	BE0089
CD3	Human	<i>in vitro</i> T cell stimulation/activation, <i>in vivo</i> T cell depletion in humanized mice, ex vivo T cell inhibition for xenografts, FC	OKT-3	BE0001-2	BE0085
CD3	Mouse	<i>in vitro</i> T cell stimulation/activation	17A2	BE0002	BE0090
CD3	Human	<i>in vivo</i> T cell depletion in humanized mice, ex vivo T cell inhibition for xenografts, FC	UCHT1 (Leu-4) (T3)	BE0231	BE0083
CD31	Mouse	<i>in vivo</i> CD31 blocking, Intravital imaging, IF, FC	390	BE0377	BE0089
CD314 (NKG2D)	Mouse	<i>in vivo</i> NKG2D blockade, <i>in vitro</i> NKG2D blockade, FC	CX5	BE0334	BE0088
CD314 (NKG2D)	Human	<i>in vitro</i> NKG2D blocking, IP, FC	1D11	BE0351	BE0083
CD317	Mouse	<i>in vivo</i> pDC depletion, IF, FC	927	BE0311	BE0090
CD32	Human	<i>in vivo</i> FcγRIIA blockade in humanized mice, <i>in vitro</i> FcγRIIA blockade, ELISA, , FC	IV.3	BE0224	BE0086
CD324 (E-Cadherin)	Mouse	<i>in vivo</i> E-Cadherin neutralization, <i>in vitro</i> E-Cadherin neutralization, IF, IP, WB	DECMA-1	BE0352	BE0088
CD326	Mouse	IHC-F IF, FC, WB	G8.8	BE0346	BE0089
CD326	Human	IHC-P IF, FC, IP	Ber-EP4	BE0386	BE0083
CD365 (TIM-1)	Mouse	<i>in vivo</i> TIM-1 blockade	RMT1-10	BE0113	BE0089
CD365 (TIM-1)	Mouse	<i>in vivo</i> TIM-1 activation, <i>in vitro</i> T cell stimulation/activation, Functional assays, ELISA, FC	3B3	BE0289	BE0089
CD365 (TIM-1)	Mouse	<i>in vivo</i> TIM-1 blockade, <i>in vitro</i> TIM-1 blockade	3D10	BE0314	BE0088
CD366 (TIM-3)	Mouse	<i>in vivo</i> TIM-3 neutralization, <i>in vitro</i> TIM-3 blocking, FC	RMT3-23	BE0115	BE0089
CD366 (TIM-3)	Mouse	<i>in vivo</i> TIM-3 neutralization, <i>in vitro</i> TIM-3 blocking, FC	B8.2C12	BE0275	BE0088
CD366 (TIM-3)	Mouse	<i>in vivo</i> TIM-3 neutralization, <i>in vitro</i> TIM-3 blocking, FC	RMT3-23	BP0115	BP0089
CD370 (CLEC9A)	Mouse	<i>in vivo</i> CLEC9A blockade, <i>in vivo</i> Ag targeting to CLEC9A+ DCs, WB, ELISA, IP, IF, FC	7H11	BE0305	BE0088
CD38	Mouse	<i>in vivo</i> CD38 stimulation, <i>in vitro</i> CD38 stimulation, <i>in vitro</i> B cell activation, IF, ELISA, FC	NIMR5	BE0317	BE0089
CD3ε	Mouse	<i>in vivo</i> T cell depletion, <i>in vitro</i> T cell stimulation/activation, IF, FC, WB	145-2C11	BE0001-1	BE0091
CD3ε	Mouse	<i>in vitro</i> T cell negative selection, <i>in vitro</i> T cell stimulation/activation, IF	KT3	BE0261	BE0089
CD3ε	Mouse	<i>in vivo</i> T cell depletion, <i>in vitro</i> T cell stimulation/activation, IF, FC, WB	145-2C11	BP0001-1	BP0091
CD3ε F	Mouse	<i>in vivo</i> T cell depletion	145-2C11 f(ab) ² Fragments	BE0001-1FAB	BE0091-FAB
CD4	Mouse	<i>in vivo</i> CD4+ T cell depletion, FC, WB	GK1.5	BE0003-1	BE0090
CD4	Human	<i>in vitro</i> T cell stimulation/activation, <i>in vivo</i> CD4+ T cell depletion in humanized mice, FC, IP	OKT-4	BE0003-2	BE0086
CD4	Mouse	<i>in vivo</i> blockade of CD4+ T-cell responses, WB	YTS 177	BE0003-3	BE0089
CD4	Mouse	<i>in vivo</i> CD4+ T cell depletion	YTS 191	BE0119	BE0090
CD4	Human	<i>in vitro</i> CD4 blockade, <i>in vitro</i> blocking of CD4+ T cell activation, IF, IHC-F, FC	RPA-T4	BE0288	BE0083
CD4	Rat	<i>in vivo</i> CD4+ T cell depletion, FC	OX-38	BE0308	BE0085
CD4	Rat	<i>in vivo</i> down-regulation of surface CD4, <i>in vitro</i> neutralization of CD4, FC, IHC-P, IHC-F	W3/25	BE0439	BE0090
CD4	Mouse	<i>in vivo</i> CD4+ T cell depletion, FC, WB	GK1.5	BP0003-1	BP0090
CD4	Mouse	<i>in vivo</i> blockade of CD4+ T-cell responses, WB	YTS 177	BP0003-3	BP0089
CD4	Rat	<i>in vivo</i> CD4+ T cell depletion, FC	OX-38	BP0308	BP0085
CD40	Mouse	<i>in vivo</i> CD40 activation, <i>in vitro</i> B cell stimulation/activation	FGK4.5/FGK45	BE0016-2	BE0089
CD40	Human	<i>in vitro</i> CD40 stimulation, Functional assays, FC	G28.5	BE0189	BE0083
CD40	Mouse	<i>in vivo</i> CD40 activation, <i>in vitro</i> B cell stimulation/activation	FGK4.5/FGK45	BP0016-2	BP0089
CD40L	Mouse	<i>in vivo</i> blocking of CD40/CD40L signaling, <i>in vitro</i> blocking of CD40/CD40L signaling, WB	MR-1	BE0017-1	BE0091
CD40L	Human, Monkey	<i>in vitro</i> blocking of CD40/CD40L signaling, <i>in vivo</i> blocking of CD40/CD40L signaling, IP, FC	5C8	BE0292	BE0085
CD40L	Mouse	<i>in vivo</i> blocking of CD40/CD40L signaling, <i>in vitro</i> blocking of CD40/CD40L signaling, WB	MR-1	BP0017-1	BP0091
CD44	Human, Mouse	<i>in vivo</i> CD44 neutralization, <i>in vitro</i> CD44 neutralization	IM7	BE0039	BE0090

Antigen	Reactivity	Application	Clone	Catalog Number	Isotype Control
CD44	Human	<i>in vivo</i> CD44 blockade in xenografts, <i>in vitro</i> CD44 blockade, WB, IF	Hermes-1	BE0262	BE0089
CD45.2	Mouse	FC, <i>in vivo</i> CD45.2 blockade, <i>in vitro</i> CD45.2 blockade, IHC-F	104.2	BE0300	BE0085
CD45RB	Mouse	<i>in vivo</i> anti-CD45RB-mediated tolerance induction, <i>in vivo</i> pre-mNK cell depletion	MB23G2 (HB220)	BE0019	BE0089
CD47	Human	<i>in vitro</i> CD47 neutralization, <i>in vivo</i> CD47 neutralization in human tumor xenograft models or humanized mice, FC	B6.H12	BE0019-1	BE0083
CD47	Mouse	<i>in vivo</i> CD47 blockade, <i>in vitro</i> CD47 blockade,IF	MIAP301	BE0270	BE0089
CD47	Human, Mouse, Rat	<i>in vivo</i> CD47 blockade, <i>in vitro</i> CD47 blocking,IF	MIAP410	BE0283	BE0083
CD47	Human, Mouse, Rat	<i>in vivo</i> CD47 blockade, <i>in vitro</i> CD47 blocking,IF	MIAP410	BP0283	BP0083
CD48	Mouse	<i>in vivo</i> CD48 blockade, <i>in vitro</i> CD48 blocking	HM48-1	BE0147	BE0091
CD49d (VLA-4)	Human, Mouse	<i>in vivo</i> VLA-4 neutralization, <i>in vitro</i> VLA-4 neutralization, FC	PS/2	BE0071	BE0090
CD54	Mouse	<i>in vivo</i> ICAM-1 neutralization, IHC-F, ELISA	YN1/1.7.4	BE0020-1	BE0090
CD54	Human	<i>in vitro</i> T cell stimulation/activation,IF	R6-5-D6	BE0020-2	BE0085
CD62E (E-selectin)	Mouse	<i>in vivo</i> E-selectin blockade, <i>in vitro</i> E-selectin blockade, IHC-F	9A9	BE0294	BE0090
CD62L(L-Selectin)	Mouse	<i>in vivo</i> CD62L neutralization	Mel-14	BE0021	BE0089
CD69	Mouse	<i>in vivo</i> down-regulation of CD69 expression, Functional assays	CD69.2.2	BE0330	BE0083
CD70	Mouse	<i>in vivo</i> CD70 blockade, <i>in vitro</i> CD70 blockade, FC	FR70	BE0022	BE0090
CD71	Human	IHC-F, IF, FC	OKT-9	BE0023	BE0083
CD71	Mouse	<i>in vivo</i> depletion of CD71+ cells	R17 217.1.3/TIB-219	BE0175	BE0089
CD71	Mouse	<i>in vivo</i> depletion of CD71+ cells, IF, IHC-F, WB	8D3	BE0329	BE0089
CD71	Mouse, Rat	Targeted drug delivery to the brain, IHC-F, FC	OX-26	BE0331	BE0085
CD71	Human	WB, IP, FC	5E9C11	BE0343	BE0083
CD71	Human	<i>in vitro</i> CD71 targeting, <i>in vivo</i> CD71 targeting,IF	B3/25	BE0367	BE0083
CD71	Human	FC, IP	T56/14	BE0370	BE0083
CD71	Human	FC*, IP*, WB*, *Based on unpublished data	2C1	BE0376	BE0086
CD71	Human	IHC-F	BK19.9	BE0388	BE0083
CD71	Canine	IHC-F, FC, WB,	1H6	BE0389	BE0083
CD71	Mouse	<i>in vivo</i> depletion of CD71+ cells, IF, IHC-F, WB	8D3	BP0329	BP0089
CD73	Mouse	<i>in vivo</i> CD73 blockade, <i>in vitro</i> CD73 blockade	TY/23	BE0209	BE0089
CD8	Mouse	<i>in vivo</i> CD8+ T cell depletion, FC	116-13.1 (HB-129)	BE0118	BE0085
CD80	Mouse	<i>in vivo</i> CD80 blockade, FC	16-10A1	BE0024	BE0091
CD80	Mouse	<i>in vivo</i> CD80 blockade, Affinity chromatography	1G10	BE0134	BE0089
CD80	Rat	<i>in vitro</i> CD80 blockade, FC	3H5	BE0187	BE0083
CD80	Mouse	<i>in vivo</i> CD80 blockade, <i>in vitro</i> CD80 blockade, FC	RM80	BE0365	BE0089
CD83	Mouse	<i>in vivo</i> CD83 blockade, <i>in vitro</i> CD83 blockade, FC, ELISA,	Michel-17	BE0398	BE0088
CD86	Mouse	<i>in vivo</i> CD86 blockade, FC	GL-1	BE0025	BE0089
CD86	Mouse	IP, FC, Functional assays,	2D10	BE0422	BE0090
CD8 α	Mouse	<i>in vivo</i> CD8+ T cell depletion, IF, FC, WB	53-6.7	BE0004-1	BE0089
CD8 α	Human	<i>in vivo</i> CD8+ T cell depletion in humanized mice	OKT-8	BE0004-2	BE0085
CD8 α	Mouse	<i>in vivo</i> CD8+ T cell depletion, WB	2.43	BE0061	BE0090
CD8 α	Mouse	<i>in vivo</i> CD8+ T cell depletion, WB	YTS 169.4	BE0117	BE0090
CD8 α	Rat	<i>in vivo</i> CD8+ T cell depletion, FC, IHC-P, IHC-F	OX-8	BE0415	BE0083
CD8 α	Mouse	<i>in vivo</i> CD8+ T cell depletion, IF, FC, WB	53-6.7	BP0004-1	BP0089
CD8 α	Mouse	<i>in vivo</i> CD8+ T cell depletion, WB	2.43	BP0061	BP0090
CD8 α	Mouse	<i>in vivo</i> CD8+ T cell depletion, WB	YTS 169.4	BP0117	BP0090
CD8 β	Mouse	<i>in vivo</i> CD8+ T cell depletion, <i>in vitro</i> CD8 blockade,IF	53-5.8	BE0223	BE0088
CD90 (Thy1)	Mouse	<i>in vitro</i> T cell depletion	M5/49.4.1	BE0076	BE0089
CD90.1 (Thy1.1)	Mouse	<i>in vivo</i> T cell depletion	19E12	BE0214	BE0085
CD90.2 (Thy1.2)	Mouse	<i>in vivo</i> ILC depletion, <i>in vivo</i> T cell depletion, WB	30H12	BE0066	BE0090
CD90.2 (Thy1.2)	Mouse	<i>in vivo</i> ILC depletion, <i>in vivo</i> T cell depletion, WB	30H12	BP0066	BP0090
CD91 (LRP1)		WB, IF, IP	11H4	BE0333	BE0083
CD96	Mouse	<i>in vivo</i> CD96 blocking, <i>in vitro</i> CD96 blocking, FC	3.3	BE0337	BE0088
CD96	Mouse		6A6/CD96	BE0403	BE0089



For the full list of our CD Marker products scan the QR code or visit us at bioxcell.com/cd-markers

For over 25 years, scientists have trusted Bio X Cell as their go-to source for *in vivo* functional grade antibodies. This is reflected in over 20,000 peer-reviewed publications citing Bio X Cell products. We understand this responsibility is of paramount importance and remain committed to producing antibodies of unparalleled quality and consistency, enabling our partners around the globe to accelerate research and discoveries.

Bio X Cell

bioxcell.com

contractservices@bioxcell.com | 1.866.787.3444

Conditions: For Research Use Only. Not for use in diagnostic or therapeutic procedures.

Not for resale.

